↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Cevian's **11%** Smith & Nephew stake is the largest new medtech activist position in two years, arriving as new CEO begins turnaround of underperforming orthopaedics unit.
11.1%
stake in Smith &
£9.8bn
medical devices company
£1.1-1.2bn
at current valuations and marks Cevian's largest new healthcare…
€1.4bn
Fresenius build in early 2022
Cevian Capital disclosed an 11.1% stake in Smith & Nephew on Tuesday, completing a two-quarter accumulation that makes the Swedish activist the largest outside shareholder in the £9.8bn medical devices company. The position, filed under UK substantial interest rules, represents roughly £1.1-1.2bn at current valuations and marks Cevian's largest new healthcare position since its €1.4bn Fresenius build in early 2022. Smith & Nephew shares closed 4.2% higher in London.
Cevian began building the stake in Q3 2024 at an average cost near 980p, according to filings reviewed by Markets Edge. The firm crossed passive thresholds in December and has now declared formal engagement intent. Smith & Nephew has traded in a 920p-1,140p range over the past twelve months, underperforming the STOXX Europe 600 Health Care index by 18 percentage points as recurring margin pressures in its orthopaedics division offset wound-care stability. The company generates $5.2bn in annual revenue across joint reconstruction, sports medicine, and advanced wound management, with 62% of sales outside the US.
The filing arrives six months after Smith & Nephew replaced CEO Deepak Nath with Siemens Healthineers veteran Donal O'Neill, who took the role in October with a mandate to reverse three years of relative margin compression. Operating margins contracted from 19.1% in 2021 to 16.4% in 2023, largely due to unfavorable product mix in hip and knee implants and slower-than-expected uptake of its Cori robotic knee platform. Cevian's historical playbook—operational streamlining, portfolio rationalization, board refreshment—fits the thesis that Smith & Nephew's sprawling device portfolio masks underinvestment in higher-margin robotics and biologics. The firm successfully pushed similar restructuring at Biomerieux and Recordati before exiting both in 2023.
Allocators watching medtech activism should note three near-term catalysts. Smith & Nephew is expected to provide 2025 guidance in late February alongside full-year results, the first full outlook under O'Neill's leadership. The company has not updated its medium-term margin target of 18-19% since 2022, and Cevian's presence increases the probability of a more aggressive roadmap or asset-sale language. Second, the board's annual re-election is scheduled for April 2025; Cevian typically negotiates director appointments within 90-120 days of crossing 10%. Third, Smith & Nephew's wound-care division—roughly 30% of revenue—has drawn inbound interest from private equity in past years, and a formal review or carve-out would unlock £2-2.5bn in proceeds at peer multiples.
Cevian now holds three public core positions: 11.1% of Smith & Nephew, 9.8% of UBS Group, and 8.4% of Brenntag. The firm exited Ericsson in Q4 2024 after a four-year engagement that returned €780m on an initial €1.1bn deployment, according to people familiar with the matter. Smith & Nephew's enterprise value of £11.2bn and net debt of $1.4bn leave room for incremental buybacks if margin expansion materializes. The next quarterly investor call is February 27.
Branded by POPS4 · proof in 60 seconds
For the principal
Consider paired exposure: long SNN against broader medtech to isolate restructuring alpha from sector beta through margin inflection cycle.
For the operator
Watch February guidance for asset-review language and margin targets; director appointments within 120 days would confirm operational engagement over passive hold.
For the house
Named accounts holding UBS or Brenntag exposure should note Cevian's capital rotation pattern: exits fund new core builds, this is third leg.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.